Rua Bioscience Sales Update

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com




FOR PUBLIC RELEASE

NZX Limited
Wellington

25 November 2024
Rua Bioscience Sales Update
E ngā iwi, ngā hapū, me ngā whānau o te motu, tēnā koutou katoa.
As we are in a period of capital raising, it is important we update you with the latest
sales information as you consider the pro-rata rights offer.
With only 3 weeks of sales in November, we are experiencing record months in both New
Zealand and Australia. With an additional week of sales remaining, this will only further
this increase.

Record month and new products in New Zealand
Sales in New Zealand have grown month-on-month, culminating in a record month for
Rua with unit sales in November 2024 greater than all previous months. As a recent
entrant to the NZ market with dried flower inhalation product this is a clear reflection of
the trust placed in Rua in our home market.
0
400
800
1200
1600
2000
D-23 J-24 F-24 M-24 A-24 M-24 J-24 J-24 A-24 S-24 0-24 N-24
to date
Unit sales by Country
AustraliaNew ZealandGermany
MARKET UPDATE

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
This is expected to grow further as we bring additional products to the market. In early
December we will be launching a new product which will be available to Doctors and
Pharmacists. It will be our second flower product, featuring the highest potency
approved for sale in New Zealand. This milestone is one that we are immensely proud
of, and we expect the product to be very well received in the market.
Australia now growing strongly
Rua is experiencing a record-breaking month for November in Australia also. More units
of Rua products were sold this month than in any other previous period and we still have
one week of sales remaining. This result is a testament to our diverse portfolio, strategic
market positioning and solid relationships with key stakeholders in the market. These
relationships are translating into repeat sales, reinforcing our long-term growth
trajectory.
Demand exceeds supply in Germany
We are experiencing regular, repeat orders in Germany but demand for our product
exceeds our supply. Despite this we have developed a strong base of demand and will
build on this as new product is delivered.
New premium product will be launched the first week of December. This is our largest
consignment purchased for Germany and we expect sales to continue to grow.
Products now in the United Kingdom
Our first portfolio of products have arrived in the UK this week and are clearing customs.
We expect these products to be available for prescription in the UK market early
December. We have been communicating with key clinics in the market ahead of the
launch and we expect greater market penetration in Q4 FY25.
Portfolio of countries
Achieving revenue in three countries, and soon to be four with the addition of the UK in
December, is a huge success for the company and creates robust and resilient revenue.
It is further evidence of Rua’s ability to execute on its strategic plan of taken unique
legacy genetics to key export and domestic markets.

ENDS  
 
The person who authorised this announcement:

Paul Naske
Chief Executive Officer
paul.naske@ruabio.com
+64 21 445154